RxDoctor Payments Data

James Roberts, MD

Ophthalmology · Largo, FLNPI 1568490407

Payments from drug & device makers

$2,157in general payments, 2019–2025

Across 93 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$707
  • Bausch & Lomb Americas Inc.$397
  • Alcon$356
  • Amgen$139
  • Shire North American Group Inc$98
  • Harrow Eye, LLC$67
  • plus $394 from 10 others

What the payments were for

  • Food & beverage$2,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,157 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$187,185
Medicare patients
810
Services billed
2,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine110$142,926
LumiganBimatoprost164$106,627
VyzultaLatanoprostene Bunod36$26,798
XiidraLifitegrast21$24,803
RhopressaNetarsudil Mesylate36$19,514
MieboPerfluorohexyloctane/Pf12$17,263
CombiganBrimonidine Tartrate/Timolol25$12,056
Latanoprost708$11,109
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$8,678
TyrvayaVarenicline Tartrate12$7,807
SimbrinzaBrinzolamide/Brimonidine Tart14$5,479
Travoprost22$3,492
Timolol Maleate193$3,372
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat192$3,323
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$2,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$707$261,609299 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$397$68,86569 claims
Aerie Pharmaceuticals, Inc.Rhopressa$15$19,51436 claims
Oyster Point Pharma, Inc.Tyrvaya$42$7,80712 claims
AlconSimbrinza$356$5,47914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →